Clark Estates Inc. NY Has $21.16 Million Position in Haleon plc (NYSE:HLN)

Clark Estates Inc. NY lowered its holdings in Haleon plc (NYSE:HLN) by 24.5% during the third quarter, HoldingsChannel.com reports. The fund owned 2,000,000 shares of the company’s stock after selling 650,000 shares during the period. Haleon accounts for 3.9% of Clark Estates Inc. NY’s portfolio, making the stock its 6th largest holding. Clark Estates Inc. NY’s holdings in Haleon were worth $21,160,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. Fortitude Family Office LLC acquired a new stake in shares of Haleon in the 3rd quarter valued at $28,000. Cultivar Capital Inc. acquired a new position in Haleon in the second quarter valued at about $40,000. Prospera Private Wealth LLC acquired a new position in Haleon in the third quarter valued at about $57,000. Hexagon Capital Partners LLC grew its stake in Haleon by 66.6% during the second quarter. Hexagon Capital Partners LLC now owns 6,695 shares of the company’s stock worth $55,000 after buying an additional 2,677 shares during the last quarter. Finally, BOKF NA raised its stake in shares of Haleon by 68.8% in the second quarter. BOKF NA now owns 6,972 shares of the company’s stock valued at $58,000 after acquiring an additional 2,842 shares during the last quarter. Institutional investors and hedge funds own 6.67% of the company’s stock.

Haleon Trading Up 0.1 %

Shares of HLN opened at $9.59 on Wednesday. The stock’s fifty day simple moving average is $9.99 and its 200-day simple moving average is $9.40. The firm has a market capitalization of $43.41 billion, a PE ratio of 28.21, a price-to-earnings-growth ratio of 2.89 and a beta of 0.30. Haleon plc has a 12-month low of $7.89 and a 12-month high of $10.80. The company has a quick ratio of 0.58, a current ratio of 0.84 and a debt-to-equity ratio of 0.44.

Analyst Upgrades and Downgrades

HLN has been the topic of several recent analyst reports. Morgan Stanley increased their price target on Haleon from $9.90 to $10.95 and gave the stock an “overweight” rating in a research report on Friday, September 20th. The Goldman Sachs Group cut Haleon from a “buy” rating to a “neutral” rating in a report on Tuesday, August 6th. UBS Group raised shares of Haleon to a “strong-buy” rating in a research note on Tuesday, October 1st. Finally, Berenberg Bank started coverage on shares of Haleon in a research note on Tuesday, August 6th. They set a “buy” rating on the stock. One investment analyst has rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $10.95.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.